CLOs on the Move

Passage Bio

www.passagebio.com

 
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.passagebio.com
  • One Commerce Square 2005 Market Street, 39th Floor
    Philadelphia, PA USA 19103
  • Phone: 267.866.0311

Executives

Name Title Contact Details
Priya Sankar
 Associate General Counsel Profile
Chip Cale
 General Counsel Profile
Edgar Chip Cale
 General Counsel Profile

Similar Companies

Ajax Health

AJAX Health accelerates medical innovation through capital and capabilities. Created in partnership with private equity leaders KKR and Aisling Capital, AJAX invests and takes an operating role in innovative medical companies that improve lives and bring speed, simplicity and cost efficiency to health care.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Xcellerex

Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EcoSynthetix

EcoSynthetix is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioMedica

BioMedica, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.